Live In Play®
Updated: 09-Jul-24 06:34 ET
IMUX:  Immunic announced that seasoned biopharmaceutical executive, Jason Tardio, will be joining the company as Chief Operating Officer and President, effective July 12, 2024  (1.16)
  • In the newly created role, Mr. Tardio will lead internal efforts to prepare for the potential launch of vidofludimus calcium (IMU-838), the company's orally available nuclear receptor related 1 (Nurr1) activator. Jason will also work closely with Patrick Walsh, Chief Business Officer, to prepare the company for a range of potential partnership outcomes for vidofludimus calcium, as well as Immunic's other drug candidates.
  • Mr. Tardio most recently served as Chief Operating Officer of Ovid Therapeutics Inc. since June 2021, after joining the company as Chief Commercial Officer in November 2019.
  • "Jason's appointment reflects our commitment to both commercial and partnership preparedness and comes at a particularly important and exciting time with the upcoming read-out of our phase 2 CALLIPER trial in progressive MS expected in April 2025 and the completion of our twin phase 3 ENSURE trials in relapsing MS expected in the second quarter and the second half of 2026, respectively. We warmly welcome him to Immunic."
Cookie Preferences

Cookie Preferences

Briefing.com uses cookies to operate the site, maintain security, remember preferences, and provide subscription features. These cookies are necessary to use Briefing.com.

We also use optional analytics cookies to understand site usage and improve our services.

View Cookie Policy
Required CookiesAlways On

These cookies are necessary to operate the site and use Briefing.com.

Analytics CookiesOptional

These cookies help us understand site usage and improve our services.

If you decline required cookies, you will not be able to use the site.

Send
Chat Icon